Selecta's Series B Adds $15M to Advance Targeted Nanoparticles

Founded in late 2007 to develop a technology platform that combines discoveries in immunobiology with advances in nanotechnology, Selecta Biosciences Inc. is ready to start moving its program toward the clinic thanks to a $15.1 million Series B round. (BioWorld Today)